Drug Profile
Research programme: cancer therapeutics - Immunome
Alternative Names: IMM 002; IMM 003; IMM 005; IMM 009; IMM 010; IMM 039Latest Information Update: 29 Dec 2022
Price :
$50
*
At a glance
- Originator Immunome
- Class CAR-T cell therapies; Gene therapies; Immunoconjugates; Immunotherapies; Monoclonal antibodies
- Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Breast cancer; Colorectal cancer; Lung cancer; Solid tumours; Unspecified
Most Recent Events
- 29 Dec 2022 Discontinued - Preclinical for Breast cancer in USA (Parenteral)
- 29 Dec 2022 Discontinued - Preclinical for Lung cancer in USA (Parenteral)
- 29 Dec 2022 Discontinued for Colorectal cancer in USA (Parenteral)